Disclosure Document

Document date:  Fri 11 Jan 2002
Published:  Fri 11 Jan 2002 00:00:00
Document No:  185999
Document part:  B
Market Flag:  Y
Classification: 

ANTISENSE THERAPEUTICS LIMITED                2002-01-11  ASX-SIGNAL-G

HOMEX - Melbourne                                                     

+++++++++++++++++++++++++
ANTISENSE THERAPEUTICS LIMITED
ACN 095 060 745

PROSPECTUS

in relation to an offer of Options to shareholders of Circadian
Technologies Limited and Syngene Limited


MESSAGE FROM THE CHIEF EXECUTIVE

As Chief Executive Officer of Antisense Therapeutics Limited
(Antisense), I have great pleasure in presenting this Prospectus.

Antisense Therapeutics Limited was formed on 13 November 2000 with
the mission to create, develop and commercialise novel antisense
pharmceuticals. This new class of therapeutic drugs is based on small
synthetic genetic molecules, with the potential to treat a wide range
of conditions and diseases including autoimmune, infectious,
inflammatory, dermatological, metabolic and cardiovascular diseases
as well as cancer.

Shares and options to take up unissued shares in Antisense commenced
official quotation on the Australian Stock Exchange (ASX) on 20
December 2001 (ASX codes ANP and ANPO respectively) pursuant to an
offer made to the public in our prospectus dated 16 November 2001
(Prospectus).

This Prospectus explains how, as an eligible shareholder of Circadian
or Syngene, you are receiving an offer of options to take up unissued
shares in Antisense at 1 cent per option. You should read this
Prospectus carefully, before making a decision to take up the options
in Antisense.

The Directors join me in offering you the opportunity to participate
in the ownership of Antisense and we look forward to welcoming you as
an optionholder of Antisense.

M Diamond
CHIEF EXECUTIVE OFFICER

MORE TO FOLLOW